替尼达普,Tenidap英语短句,例句大全

替尼达普,Tenidap
1)Tenidap替尼达普
1.3 channel and the pathogenesis of chronic temporal lobe epilepsy;to investigate the effect of tenidap,an special opener of Kir2.3通道特异性开放剂替尼达普对慢性颞叶癫痫大鼠行为学、Kir2。
2)dasatinib达沙替尼
1.Generalized myalgia,ostalgia and arthralgia attributed to dasatinib达沙替尼致全身肌肉骨骼关节疼痛
2.Study on synthetic process of dasatinib达沙替尼的合成工艺研究
3.The chloro groups of 4,6-dichloro-2-methylpyrimidine were successively substituted with amino group of 5,and N-hydroxyethylpiperazine to give antitumor agent dasatinib monohydrate in 52%overall yield.最后4,6-二氯-2-甲基嘧啶先与5进行亲核取代反应,再与N-羟乙基哌嗪发生亲核取代反应制得抗肿瘤药达沙替尼—水合物,总收率约52%。
3)Synthesis of Dasatinib达沙替尼的合成
4)sunitinib舒尼替尼
1.Advance in research of sunitinib,a multitargeted receptor tyrosine kinase inhibitor;多靶点酪氨酸激酶抑制剂舒尼替尼的研究进展
2.Pharmaceutical Care of Clinical Pharmacist for a Cancer Patient Taking Molecular Targeted Drug:Sunitinib临床药师对1例服用分子靶向药物舒尼替尼的肿瘤患者的药学监护

英文短句/例句

1.Sunitinib as a molecular targeting agent in renal cell carcinoma分子靶向药物舒尼替尼治疗肾细胞癌
2.The Synthesis of a Targeted Anti-tumor Agent-sunitinib Malate;肿瘤靶向治疗药物苹果酸舒尼替尼的合成研究
3.Progression in the study of clinical pharmacoeconomics of sunitinib for metastatic renal cell carcinoma舒尼替尼治疗转移性肾细胞癌的临床药物经济学研究进展
4.Giventhe short period of follow-up in the research, the effect of thetreatment on survival rates could not be corroborated.研究跟踪报道接受舒尼替尼短期治疗后尚未发现能提高患者生存率。
5.Pharmaceutical Care of Clinical Pharmacist for a Cancer Patient Taking Molecular Targeted Drug:Sunitinib临床药师对1例服用分子靶向药物舒尼替尼的肿瘤患者的药学监护
6.Nimesulide suppositories and nimesulide tablets were not bioeqivalent.尼美舒利栓剂与尼美舒利片剂生物不等效。
7.Transmissio iustinianea (ex iure deliberandi)优士丁尼转位（替换）
8.Bronia was a genius for making things comfortable.布朗尼娅善于把事情安排得舒舒服服。
9.Sufentanil in PCIA in Patients of Old Ages老年患者舒芬太尼术后静脉自控镇痛
10.Preparation and Pharmacokinetics of Sustained Release Suppositories of Nimesulide尼美舒利缓释栓的制备与药动学研究
11.Clinical Observation of Gefitinib and Eelotinib in Treatment with Non-small Cell Lung Cancer吉非替尼与厄罗替尼治疗晚期非小细胞肺癌的临床分析
12.Determination of Ranitidine Hydrochloride in Compound Ranitidine Dispersing Tablet复方雷尼替丁分散片中盐酸雷尼替丁含量测定研究
13.Lapatinib in Combination with Bortezomib Inhibits Breast Cancer Cells Growth and the Activity of Bortezomib to Lapatinib-resistant Breast Cancer Cell拉帕替尼联合硼替佐米抑制乳腺癌细胞生长及硼替佐米对拉帕替尼耐药细胞的活性的研究
14.Therefore the Venetian world makes him their scapegoat.因此，威尼斯的世界将他当替罪羔羊。
15.Anthony, I want you to play back up for Justin.安东尼，我想要你作为贾斯廷的替补。
16.Study on the Synthetic Process of Erlotinib and Its Intermediates厄洛替尼及其中间体的合成工艺研究
17.Gifitinib in the Treatment for 22 Cases with Advanced Non-small Cell Lung Cancer吉非替尼治疗22例晚期非小细胞肺癌
18.Determination of ranitidine hydrochloride capsules by HPLCHPLC测定盐酸雷尼替丁胶囊的含量

相关短句/例句

dasatinib达沙替尼
1.Generalized myalgia,ostalgia and arthralgia attributed to dasatinib达沙替尼致全身肌肉骨骼关节疼痛
2.Study on synthetic process of dasatinib达沙替尼的合成工艺研究
3.The chloro groups of 4,6-dichloro-2-methylpyrimidine were successively substituted with amino group of 5,and N-hydroxyethylpiperazine to give antitumor agent dasatinib monohydrate in 52%overall yield.最后4,6-二氯-2-甲基嘧啶先与5进行亲核取代反应,再与N-羟乙基哌嗪发生亲核取代反应制得抗肿瘤药达沙替尼—水合物,总收率约52%。
3)Synthesis of Dasatinib达沙替尼的合成
4)sunitinib舒尼替尼
1.Advance in research of sunitinib,a multitargeted receptor tyrosine kinase inhibitor;多靶点酪氨酸激酶抑制剂舒尼替尼的研究进展
2.Pharmaceutical Care of Clinical Pharmacist for a Cancer Patient Taking Molecular Targeted Drug:Sunitinib临床药师对1例服用分子靶向药物舒尼替尼的肿瘤患者的药学监护
5)nilotinib尼罗替尼
1.Pharmacology and clinical evaluation of nilotinib,a Bcr-Abl tyrosine kinase inhibitor;Bcr-Abl激酶抑制剂尼罗替尼的药理与临床评价
2.After deprotection, the antitumor agent nilotinib was obtained with an overall yield of 40% based on compound 5.另用3-氨基-4-甲基苯甲酸乙酯(5)与氨腈成胍6,6与3-二甲胺基-1-(3-吡啶基)-2-丙烯-1-酮环合得4-甲基-3-[[4-(3-吡啶基)-2-嘧啶基]氨基]苯甲酸乙酯(8),8经叔丁氧羰基保护、水解,再与4经酰胺化、脱保护后得到尼罗替尼,总收率40%(以5计)。
6)tenecteplase替奈替普酶
1.Tenecteplase based on the alteplase is the third generation thrombolytic agent,Th~(103)、Asn~(117) and Lys~(296)-His-Arg-Arg~(299) in alteplase molecule are replaced by Asn、Glu and Ala-Ala-Ala-Ala in tenecteplase.替奈替普酶(Tenecteplase)是在阿替普酶(Alteplase)的基础上,用Asn、Glu和Ala-Ala-Ala-Ala代替其分子中的Th103、Asn117和Lys296-His-Arg-Arg2993个位点而得到的生物技术制品,属于新型的第3代溶栓药,具有体内半衰期长,溶栓效果好,溶栓时间短,纤维蛋白特异识别性强,使用方便及危险性低等特点。